The third edition of Fever FM's SuperWomaniya Awards 2024 was held at the ITC Grand Central hotel in Mumbai, and several stars made sure to walk the blue carpet.
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.
Nayar believes that the whole team has bought into Rohit and Gambhir's philosophy, including the two spin greats.
Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after analysts remained cautious on the company's Q3 performance and differed on its growth outlook. DRL's Q3 performance was viewed as subdued by some analysts when they adjusted it for one-time grants and incomes that the company received during the quarter.
'We have to be prepared for the larger disruption that is likely to take place.'
'A long-term investor with a 4 to 5 year horizon could invest in this theme via SIPs.'
Experts believe the move will have little impact given limited production of generic drugs and authority of doctors in prescribing medicines.
Divya Nair/Rediff.com speaks to students and experts to find out whether it is better to study management in India or try for an international MBA.
'Many were caught in a burnout race, chasing unsustainable growth without innovating.'
Despatch just goes on and on, sighs Mayur Sanap.
US markets have been very lucrative for the Indian pharma companies and many companies such as Ranbaxy and Dr Reddy's capitalised on this opportunity.
Christmas romance, heists, thrillers, it's all there on OTT this week. Sukanya Verma lists her recommendations.
Donald Trump's Presidency of the United States will open new opportunities for India though certain sectors, especially pharma and IT, may face the heat if the incoming president decides to impose restrictions on imports and H1B visa regulations, experts said on Wednesday. Prime Minister Narendra Modi's friendly relationship with Trump will have a positive bearing on Indo-US relations but India may have to adapt its strategies to maintain cooperation in areas of mutual interest.
If Naam was made today, there wouldn't even have been enough audiences to boo it out of the halls, observes Deepa Gahlot.
The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world's largest generics maker. Teva is next on the list. Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.
The company has entered into a tie-up with the US-based FSC Laboratories as its authorised generic partner for FSC's hypertension medicine Isoptin SR (Verapamil SR) in the US.
It has become difficult for Ashwin to be even considered in the present scenario.
Closure would mean manufacturer might not be able to launch any new generic products in India in future.
The judge further underlined that the minorities of the country had not only joined the mainstream but also were an important facet of it.
Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period in-between, according to data compiled from Bloomberg and company annual reports. Also, these companies more than doubled their R&D spending in absolute terms over these five years: From Rs 25,041 crore to Rs 63,072 crore. While this reflects a prioritisation of innovation, corporate R&D investment remains relatively conservative.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
What makes Pushpa 2 float is Allu Arjun's magnetic performance. The actor really goes an extra mile to deliver the wildfire he promised, observes Mayur Sanap.
Charging the multinational companies with making several drugs beyond the reach of the poor, visiting Commerce Minister Anand Sharma today asserted it is the Indian generics which have challenged such a "suffocating stranglehold" and made the medicines affordable.
Regulator says fee would enable it to quicken approval process.
Ask rediffGURU and PF and MF expert Janak Patel your mutual fund and personal finance-related questions.
Generic drugmakers cannot be sued under state law for adverse reactions to their products.
The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.
Banerjee had on Wednesday said an amendment to existing laws will be passed in the state assembly next week to ensure capital punishment to convicted rapists.
Arjun Menon looks at the Top 10 South films that made an impact in 2024.
'There is no reason why we should break this business up.'
Watch her in hand-to-hand combat, wielding guns, firing weapons and breaking bones like a beast in some of the sleekly done one-take sequences. She also owns some emotionally-charged moments within the same dramatic beat, observes Mayur Sanap.
'API prices are dragging down margins and impacting our competitive ability.'
Continued demand for generics from the US market will ensure stable outlook for Indian Generics Pharmaceuticals in 2011, global rating agency Fitch Ratings said on Monday.
India's biggest drug maker Ranbaxy Laboratories Ltd has put in its bid to acquire generic business of German pharmaceutical firm Merck.
Amaran is effective as a intimate, well researched piece of storytelling but does not try to break any new ground, observes Arjun Menon.
The drug that it would supply is called Olanzapine, used to treat schizophrenia and bipolar disorder.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances